Candel Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 10 →Insiders1 insider bought $3.0M in 1 open-market buy. 3 insiders sold $3.6M, all 5 sales on a 10b5-1 plan.→HoldersFMR 14.4%RTW Investments 8.4%BlackRock 6.5%→Financing →PeersClosest companies: ZBIO, IBRX, SLS→
From the filings
Figures
- Net income
- −$88.5Mlast 12 months
- Operating cash flow
- −$47.7Mlast 12 months
- Cash and equivalents
- $201.6Mat the last balance sheet
- Total debt
- $0.00at the last balance sheet
- Shares outstanding
- 76.1M shareson issue